Palisade Bio (PALI) announced that the first patients have been dosed in its Phase 1b clinical study evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 inhibitor prodrug, for the treatment of fibrostenotic Crohn’s disease. Topline data are anticipated in the first quarter of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio Regains Nasdaq Compliance on Stock Price
- Palisade Bio granted Canadian patent covering PALI-2108 composition
- Palisade Bio Cancels Stockholder Meeting Due to Quorum
- Palisade Bio prices 171.4M shares at 70c in upsized underwritten public offering
- Palisade Bio files to sell 147.1M shares of common stock